Backs FY25 revenue view $3B-$3.1B, consensus $3.03B. Backs FY25 adjusted EBITDA view $650M-$675M.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals reports Q1 adjusted EPS 21c, consensus 15c
- AMRX Earnings this Week: How Will it Perform?
- Amneal Pharmaceuticals announces expanded coverage for Crexont
- Amneal Pharmaceuticals announces U.S. launch of Boruzu
- Amneal Pharmaceuticals (AMRX) Stock Soars 45% on Success of New Parkinson’s Treatment